Navigation Links
Cyberonics to Present at Maxim Group Growth Conference
Date:9/17/2009

HOUSTON, Sept. 17 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that James Reinstein, Cyberonics' Vice President, Sales & Marketing and General Manager, International, will present at the Maxim Group Growth Conference in New York on Tuesday, September 29, 2009 at 2:30 PM EDT. Maxim will host a webcast of the presentation live and by replay at http://www.wsw.com/webcast/maxim2/cybx/. The replay will be available for 90 days following the conference. Presentation slides will be available on-line at www.cyberonics.com by 8:00 AM EDT on Tuesday, September 29, 2009. The presentation can also be accessed at www.cyberonics.com by clicking on the link for this webcast. Access to the webcast is not password protected.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (Nasdaq: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.

    CONTACT INFORMATION:
    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd.
    Houston, TX 77058
    Main:  (281) 228-7262
    Fax:  (281) 218-9332
    ir@cyberonics.com


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cyberonics to Present at UBS Global Life Sciences Conference
2. Cyberonics Reports Strong Fiscal 2010 First Quarter Results
3. Cyberonics to Present at Canaccord Adams 29th Annual Global Growth Conference
4. Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financial Results
5. Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan
6. Cyberonics Names Bryan D. Olin, Ph.D. Vice President, Quality
7. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
8. Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter
9. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results
10. Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development
11. Cyberonics to Present at Piper Jaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Groth Family ... Pasco and Richland, is initiating a charity drive to support the family of ... recent automobile collision. , On October 29th of this year, Cindy Hendrickson ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
Breaking Medicine Technology: